KBC Group’s Integra LifeSciences IART Stock Holding History

KBC Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,839	Closed	-$62K	–	1759
2025 Q1	$62K	Hold	2,839	–	–	﹤0.01%	1722
2024 Q4	$64K	Hold	2,839	–	–	﹤0.01%	1765
2024 Q3	$52K	Buy	2,839 +1,120	+65%	+$26K	﹤0.01%	1692
2024 Q2	$50K	Hold	1,719	–	–	﹤0.01%	1617
2024 Q1	$61K	Buy	1,719 +595	+53%	+$23.8K	﹤0.01%	1428
2023 Q4	$49K	Hold	1,124	–	–	﹤0.01%	1543
2023 Q3	$43K	Buy	+1,124	New	+$47.3K	﹤0.01%	1565
2014 Q2	–	Sell	-1,730	Closed	-$33K	–	1346
2014 Q1	$33K	Sell	1,730 -2,781	-62%	-$53.7K	﹤0.01%	1239
2013 Q4	$88K	Sell	4,511 -25,600	-85%	-$470K	﹤0.01%	1168
2013 Q3	$496K	Hold	30,111	–	–	0.01%	821
2013 Q2	$451K	Buy	+30,111	New	+$441K	0.01%	835

Other funds holding IART

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KBC Group's IART Position: Q2 2025 in Review

KBC Group sold out of Integra LifeSciences (IART) in Q2 2025, closing a stake of 2,839 shares — an estimated $62K sold.

KBC Group first reported a position in IART in Q2 2013 and held it in 11 quarters. The position peaked at $496K in Q3 2013. 208 funds tracked by Wall St. Rank hold IART as of Q2 2025.

KBC Group reported no remaining Integra LifeSciences position as of Q2 2025 after selling out during the quarter.
KBC Group sold 2,839 Integra LifeSciences shares in Q2 2025, an estimated $62K.
KBC Group first reported a position in Integra LifeSciences in Q2 2013 and held it in 11 quarters.
KBC Group's Integra LifeSciences position peaked at $496K in Q3 2013.
208 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2025.

Based on KBC Group's 13F filing for Q2 2025, filed 8 Aug 2025.